Large-scale testing (Phase 3)UnknownNCT01352091What this trial is testingAdjuvant AI Combined With ZoladexWho this might be right forBreast Cancer Fudan University 670
Large-scale testing (Phase 3)WithdrawnNCT06585969What this trial is testingA Randomised Trial Comparing Trastuzumab Deruxtecan to CDK4/6 Inhibitors in Non-luminal A, ER-positive/HER2-low Metastatic Breast CancerWho this might be right forMetastatic Breast CancerER-positive Breast CancerLuminal B+2 more Danish Breast Cancer Cooperative Group
Testing effectiveness (Phase 2)UnknownNCT01283789What this trial is testingLapatinib and RAD-001 for HER2 Positive Metastatic Breast CancerWho this might be right forMetastatic Breast Cancer University of Kansas Medical Center 23
Testing effectiveness (Phase 2)UnknownNCT01266213What this trial is testingFulvestrant (F)/Goserelin (G) vs Anastrozole (A)/G vs G for Premenopausal WomenWho this might be right forMetastatic Breast CancerEstrogen Receptor Positive TumorBreast Cancer Nos Premenopausal Samsung Medical Center 147
Testing effectiveness (Phase 2)Looking for participantsNCT06927180What this trial is testingSHR-A1811 Plus Pertuzumab in the Neoadjuvant Treatment of HER2 Positive BCWho this might be right forBreast Cancer Early Stage Breast Cancer (Stage 1-3) Henan Cancer Hospital 180
Not applicableUnknownNCT05656079What this trial is testingTo Evaluate the Cardiac Safety of Pegylated Liposomal Doxorubicin Concurrently Plus Trastuzumab and Pertuzumab in the Adjuvant Setting for Early-stage HER-2-positive Breast Cancer: a Multicenter, Randomized Controlled Clinical StudyWho this might be right forBreast Cancer Shanghai Pudong Hospital 204
Testing effectiveness (Phase 2)Ended earlyNCT02379585What this trial is testingFasting on Newly Diagnosed Breast CancerWho this might be right forHER2-positive Breast Cancer Western Regional Medical Center 8
Large-scale testing (Phase 3)Study completedNCT00390455What this trial is testingFulvestrant With or Without Lapatinib in Treating Postmenopausal Women With Stage III or Stage IV Breast Cancer That is Hormone Receptor-PositiveWho this might be right forEstrogen Receptor PositiveHER2 Positive Breast CarcinomaHER2/Neu Negative+5 more National Cancer Institute (NCI) 295
Post-approval studies (Phase 4)Ended earlyNCT04031885What this trial is testingAbemaciclib (LY2835219) in Combination With Fulvestrant Compared to Chemotherapy in Women With HR Positive, HER2 Negative Metastatic Breast CancerWho this might be right forMetastatic Breast Cancer Eli Lilly and Company 4
Testing effectiveness (Phase 2)Looking for participantsNCT07220135What this trial is testingTrial of Neoadjuvant THP vs TCHP for HER2-Amplified/Positive Breast CancerWho this might be right forBreast Cancer University of Kansas Medical Center 100
Testing effectiveness (Phase 2)UnknownNCT04318223What this trial is testingPalbociclib Plus Fulvestrant in Women With Hormone Receptor Positive and Human Epidermal Growth Factor Receptor Type 2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated With a CDK4/6 Inhibitor in Combination With Hormonal TherapyWho this might be right forMetastatic Breast CancerLocally Advanced Breast Cancer Consorzio Oncotech 168
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07410559What this trial is testingNeoadjuvant Imlunestrant Plus Abemaciclib Treatment Guided by Ki67 Index After 2 Weeks for ER-Positive HER2-Negative Breast CancerWho this might be right forBreast Cancer Fudan University 189
Early research (Phase 1)Study completedNCT01969643What this trial is testingA Safety Study of SGN-LIV1A in Breast Cancer PatientsWho this might be right forHER2 Positive Breast NeoplasmsHormone Receptor Positive Breast NeoplasmsTriple Negative Breast Neoplasms+1 more Seagen Inc. 290
Testing effectiveness (Phase 2)Study completedNCT00755885What this trial is testingAbiraterone Acetate in Treating Postmenopausal Women With Advanced or Metastatic Breast CancerWho this might be right forBreast Cancer Cancer Research UK 77
Testing effectiveness (Phase 2)UnknownNCT04034589What this trial is testingPyrotinib in Combination With Fulvestrant in Patients With HER2 Positive，HR-Positive Metastatic Breast CancerWho this might be right forMetastatic Breast Cancer Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University 46
Early research (Phase 1)Ended earlyNCT02095210What this trial is testingHER2 PET Imaging in Breast Cancer Patients Using [68GA]ABY-025Who this might be right forHER2-positive Breast Cancer Dorte Nielsen 2
Testing effectiveness (Phase 2)Not Yet RecruitingNCT05979220What this trial is testingStudy of Dalpiciclib Combined With Letrozole in the Maintenance Treatment of HR Positive and HER2 Negative Metastatic Breast Cancer After First-line ChemotherapyWho this might be right forBreast Cancer Shuangyue Liu 178
Large-scale testing (Phase 3)Active Not RecruitingNCT04784715What this trial is testingTrastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)Who this might be right forBreast Cancer; HER2-positive; Metastatic AstraZeneca 1,157
Early research (Phase 1)Active Not RecruitingNCT05509790What this trial is testingLY3484356 in Chinese Participants With Advanced Breast CancerWho this might be right forBreast Neoplasms Eli Lilly and Company 17
Not applicableNot Yet RecruitingNCT07593196What this trial is testingHER2-positive Metastatic Breast Cancer in KazakhstanWho this might be right forMetastatic Breast Cancer AstraZeneca 240